Cost-Effectiveness Analysis of Daratumumab Monotherapy and Subsequent Therapies in Heavily Treated Relapsed/Refractory Multiple Myeloma: A Feasible Methodology using a Korean Nationwide Population Cohort.

Cancer Res Treat · 2026 · PMC12800944 · PMID 40241581

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

While daratumumab monotherapy’s efficacy in terms of TTNT did not reach statistical significance, this treatment demonstrated superior outcomes in TTNT2 and OS, likely reflecting the pharmacological properties of daratumumab highlighted in previous literature.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.